LSTA

#4144
Lisata Therapeutics, Inc. - Common Stock
3.2 5 USD
-1.81%
Secteur: Soins de Santé
Base: USD
Devise de Profit: USD
Range quotidien
3.25
3.25
Range Annuel
1.81
5.06
Changement quotidien
-1.81%
Changement Mensuel
+1.25%
Evolution sur 6 mois
+58.54%
Changement Annuel
+16.49%
Clôture Précédente
3.3 1
Open
3.2 5
Low
3.2 5
High
3.2 5
Volume
4
Afficher le graphique complet Full chart

Financials

Aperçu Relevé Statistiques
Trimestriel Annuel
  • Market Capitalization 29.6 M
  • Employee 21
  • Founded 1980
  • CEO N/A
  • Website www.lisata.com
  • Headquarter Delaware, United States
  • FIGI BBG000BNVDR4
  • Industry Biotechnologies
Chiffre d'affaires total
Résultat net
Bénéfice par action de base (BPA de base)
Dette totale
Flux de trésorerie disponible
Trésorerie et équivalents de trésorerie
ratio cours/bénéfice
-0.97
ratio cours/chiffre d'affaires
95.05

Lisata Therapeutics, Inc. - Common Stock

Lisata Therapeutics is an American clinical stage pharmaceutical company active in the field of oncology, specifically aimed at developing and commercializing new cancer therapies. It was formed through a merger of Cend Therapeutics and Caladrius Biosciences in September 2022. In 2019, the FDA granted their product, certepetide, orphan drug status in pancreatic cancer, followed by a Fast track status in 2022. Non-clinical data collected by Lisata and others have demonstrated enhanced delivery of various existing and emerging anti-cancer therapies, including chemotherapies, immunotherapies and RNA-based therapeutics when used with certepetide.

Nouvelles